HRS-9813 Clinical Trials (2026): 5 Studies for Pulmonary Fibrosis & Healthy Volunteers
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 HRS-9813 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Pulmonary Fibrosis & Healthy Volunteers) and 397 total planned enrollment. 2 HRS-9813 clinical trials are actively recruiting. Most recent activity: NCT07192939 (Jun 2028).
HRS-9813 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | Total |
|---|---|---|---|
| P1 | 1 | 3 | 4 |
| P2 | 1 | 1 |
Recruiting HRS-9813 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07192939 | Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis | P2 | IPF and PPF | 270 | Oct 2025 |
| NCT07229716 | Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects | P1 | Pulmonary Fibrosis | 20 | Apr 2026 |
HRS-9813 clinical trials by indication
Pulmonary Fibrosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07229716 | — | P1 | recruiting | Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects |
| NCT06939504 | — | P1 | completed | A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects |
IPF and PPF (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07192939 | — | P2 | recruiting | Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis |
Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06821464 | — | P1 | completed | A Trial of HRS-9813 in Healthy Subjects |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06514963 | — | P1 | completed | A Trial of HRS-9813 in Healthy Volunteers |
All HRS-9813 trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07192939 | Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis | P2 | recruiting | 270 | Guangdong Hengrui Pharmaceutical Co., Ltd | Oct 2025 | |
| NCT07229716 | Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects | P1 | recruiting | 20 | Guangdong Hengrui Pharmaceutical Co., Ltd | Apr 2026 | |
| NCT06821464 | A Trial of HRS-9813 in Healthy Subjects | P1 | completed | 45 | Guangdong Hengrui Pharmaceutical Co., Ltd | Feb 2025 | |
| NCT06939504 | A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects | P1 | completed | 12 | Guangdong Hengrui Pharmaceutical Co., Ltd | May 2025 | |
| NCT06514963 | A Trial of HRS-9813 in Healthy Volunteers | P1 | completed | 50 | Guangdong Hengrui Pharmaceutical Co., Ltd | Jul 2024 |
HRS-9813 clinical trials: frequently asked questions
- How many HRS-9813 clinical trials are there?
- 5 HRS-9813 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 3 are marked completed.
- Are HRS-9813 clinical trials recruiting in 2026?
- Yes — 2 HRS-9813 trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is HRS-9813 being studied for?
- HRS-9813 is being studied for Pulmonary Fibrosis, Healthy Volunteers, Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis, IPF and PPF. The trials are grouped by indication on this page.
- What phase is HRS-9813 in?
- HRS-9813 clinical trials span 1 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors HRS-9813 clinical trials?
- The lead sponsor across the most HRS-9813 trials is Guangdong Hengrui Pharmaceutical Co., Ltd. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming HRS-9813as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: